TY  - JOUR
AU  - Ángel Calleja, Miguel
AU  - Navarro, Andrés
AU  - Serratosa, José María
AU  - Toledo, Manuel
AU  - Villanueva, Vicente
AU  - Subías Labazuy, Silvia
AU  - Gil, Alicia
PY  - 2022
DO  - 10.1080/14737167.2022.2107507
UR  - http://hdl.handle.net/10668/19682
T2  - Expert review of pharmacoeconomics & outcomes research
AB  - To determine the economically justifiable price (EJP) of cenobamate to become a cost-effective alternative compared with third-generation anti-seizure medications in the treatment of focal-onset seizures (FOS) in adult patients with drug-resistant...
LA  - en
KW  - Anti-seizure medications
KW  - Spain
KW  - cenobamate
KW  - cost-effectiveness
KW  - drug-resistant epilepsy
KW  - economically justifiable price
KW  - Adult
KW  - Carbamates
KW  - Chlorophenols
KW  - Cost-Benefit Analysis
KW  - Epilepsy
KW  - Humans
KW  - Lacosamide
KW  - Quality-Adjusted Life Years
KW  - Spain
KW  - Tetrazoles
TI  - Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
TY  - research article
VL  - 22
ER  -